Cowingene Launches Advanced Lyophilized PCR Kit for Rapid Detection of Group B Streptococcus in Pregnancy Screening

In a significant step forward for maternal and neonatal health, Cowin, a fast-growing innovator in molecular diagnostics, has introduced its latest solution: the Cowingene Group B Streptococcus Detection Kit (Lyophilized) Designed for precise, efficient, and accessible screening, the new kit addresses a critical need in prenatal care—the timely detection of Group B Streptococcus (GBS), a bacterium that can pose serious risks to newborns if left undetected.

Addressing a Critical Clinical Need

Group B Streptococcus is a common bacterium often found in the digestive and lower reproductive tracts of healthy adults. While it is usually harmless in adults, it can cause severe infections in newborns, including sepsis, pneumonia, and meningitis. According to global clinical guidelines, pregnant women are routinely screened for GBS between the 36th and 37th week of pregnancy to reduce the risk of early-onset GBS disease in infants.

The newly launched Cowingene GBS Detection Kit is specifically developed for in vitro qualitative detection of GBS in female vaginal swab samples, providing healthcare providers with a reliable diagnostic tool to support preventive care strategies.

Advanced PCR Technology for High Sensitivity

At the core of the Cowingene detection kit is a robust PCR amplification method combined with fluorescent probe technology. This advanced approach enables the kit to target highly conserved gene regions specific to Group B Streptococcus, ensuring both high specificity and sensitivity.

The kit achieves a limit of detection (LoD) of 400 copies/mL, making it capable of identifying even low levels of bacterial presence. This level of sensitivity is crucial for early detection and timely clinical intervention.

In addition, the kit incorporates an endogenous internal control, which serves as a built-in quality assurance mechanism. This feature ensures that the entire testing process—from sample preparation to amplification—is functioning correctly, reducing the likelihood of false-negative results.

Lyophilized Format Enhances Stability and Convenience

One of the standout features of the Cowingene GBS Detection Kit is its lyophilized (freeze-dried) format. This innovation brings multiple practical advantages:

Extended shelf life: The kit remains stable for up to 18 months when stored at 2–30°C.

Simplified logistics: It can be transported at room temperature (2–30°C) for up to 15 days without compromising performance.

Ease of use: Pre-formulated lyophilized reagents reduce preparation steps, minimizing human error and improving workflow efficiency.

This format is especially beneficial for laboratories and healthcare facilities in regions with limited cold-chain infrastructure, supporting broader accessibility to high-quality molecular diagnostics.

Broad Instrument Compatibility

The Cowingene GBS Detection Kit is designed with flexibility in mind. It is compatible with a wide range of open real-time PCR platforms that support multiple fluorescence channels, including FAM, VIC/HEX, ROX, and CY5.

Commonly supported instruments include:

ABI 7500 systems

Roche LightCycler 480

Bio-Rad CFX96

This compatibility allows laboratories to integrate the kit seamlessly into existing workflows without requiring additional equipment investment.

Comprehensive Product Configuration

Each kit (REF: ST06012X) contains sufficient reagents for 48 tests, making it suitable for both routine screening and medium-scale laboratory operations. The product is certified under CE-IVD, confirming its compliance with international standards for in vitro diagnostic medical devices.

To further enhance testing performance, Cowin also offers a range of recommended supporting reagents, including:

Viral DNA/RNA extraction columns

Sample release reagents

Self-collection vaginal sampling kits

DNA/RNA extraction kits

These complementary products provide laboratories with a complete, end-to-end testing solution, improving consistency and efficiency across the diagnostic process.

Optimized Storage and Handling

The kit is engineered with practical usage conditions in mind. Key storage and handling features include:

Stable at 2–30°C for up to 18 months

Opened reagents remain valid for 7 days at 2–8°C

Certain components can be stored for up to one month below -20°C

Designed to withstand up to 10 freeze-thaw cycles

These flexible conditions allow laboratories to manage inventory efficiently while maintaining assay reliability.

Supporting Preventive Maternal Healthcare

The introduction of this GBS detection kit aligns with global efforts to improve maternal and neonatal outcomes through early diagnosis and preventive care. By enabling accurate screening during late pregnancy, healthcare providers can take timely measures—such as administering intrapartum antibiotics—to significantly reduce the risk of neonatal infection.

The ability to deliver rapid, reliable results also helps streamline clinical decision-making, ensuring that patients receive appropriate care without unnecessary delays.

Cowin’s Commitment to Molecular Diagnostics Innovation

The launch of the Cowingene GBS Detection Kit reflects Cowin’s broader mission to advance healthcare through innovation. As a young and dynamic company specializing in molecular point-of-care testing (POCT) and in vitro diagnostic reagents, Cowin has rapidly positioned itself as a promising player in the global diagnostics market.

With a strong focus on research and development, the company leverages a professional team and a culture of innovation to create solutions that are:

Efficient – reducing testing time and complexity

Accessible – adaptable to diverse healthcare environments

Intelligent – integrating quality control and advanced detection technologies

Cowin aims to become a trusted partner in molecular diagnostics, delivering products that empower healthcare providers and improve patient outcomes worldwide.

Expanding Access to Reliable Diagnostics

In many parts of the world, access to high-quality diagnostic tools remains a challenge. By offering a stable, easy-to-use, and highly accurate GBS detection kit, Cowin is contributing to the global effort to bridge this gap.

The lyophilized format, in particular, represents a meaningful step toward decentralizing molecular testing, making it more feasible for use in smaller clinics, regional laboratories, and resource-limited settings.

Looking Ahead

As molecular diagnostics continues to evolve, the demand for rapid, accurate, and user-friendly testing solutions will only increase. Products like the Cowingene Group B Streptococcus Detection Kit demonstrate how innovation can directly address real-world healthcare challenges.

By combining advanced PCR technology, practical design, and a strong commitment to quality, Cowin is helping shape the future of prenatal screening and infectious disease diagnostics.

With continued investment in research and global collaboration, the company is well-positioned to expand its portfolio and further strengthen its role in improving health outcomes across diverse populations.

Conclusion

The Cowingene Group B Streptococcus Detection Kit (Lyophilized) represents a comprehensive and forward-thinking solution for prenatal GBS screening. Its high sensitivity, robust quality control, flexible storage, and broad compatibility make it a valuable addition to modern diagnostic laboratories.

As healthcare systems worldwide place increasing emphasis on early detection and prevention, innovations like this will play a crucial role in safeguarding maternal and neonatal health—delivering not just better diagnostics, but better lives.